Antitumor effect of novel silatranes on renal cell carcinoma in mice.
The effect of several novel silatrane derivatives on the growth of syngeneic renal cell carcinoma (RENCA) in BALB/c mice and the survival rate of the animals were evaluated. The RENCA-bearing animals were treated subcutaneously and weekly with either a water-insoluble or a water-soluble derivative. The silatrane-treated animals were either free of palpable tumors or developed tumors much more slowly in comparison with the control animals without silatranes. The treated animals as a whole also died of tumor at much slower rates. Attempts to use higher silatrane dosages to achieve better curative effects were hampered by the toxicity of these compounds.
Grna
A
A
Department of Microbiology and Immunology, Northeastern Ohio Universities College of Medicine, Rootstown 44272.
Koo
P H
PH
Hogan
J
J
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology / Q000627:therapeutic use*; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D005260:Female; D007680:Kidney Neoplasms / Q000188:drug therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D017646:Organosilicon Compounds; D012825:Silicon / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D001643:Bridged Bicyclo Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D017646:Organosilicon Compounds; C015503:silatrane; D012825:Silicon